The prevalence of SARS-CoV-2 infection in chronic inflammatory rheumatic diseases has not yet been widely reported, and has been evaluated only in symptomatic patient samples. The proportion of asymptomatic or mildly symptomatic patients is unknown, in patients who share common symptoms with CoV-2-SARS infection. Our objective is to describe the prevalence of seroconversion to CoV-2-SARS by consecutive screening in routine care of patients with chronic inflammatory rheumatism with serological testing
The prevalence of SARS-CoV-2 infection in chronic inflammatory rheumatic diseases has not yet
been widely reported, and has been evaluated only in symptomatic patient samples. The
proportion of asymptomatic or mildly symptomatic patients is unknown, in patients who share
common symptoms with CoV-2-SARS infection.
Some treatments for chronic inflammatory rheumatisms such as TNF inibitors appear to have a
protective effect against severe forms of COVID-19, while corticosteroids or other
immunosuppressants may be associated with a higher prevalence of severe forms of COVID-19.
Our objective is to describe the prevalence of seroconversion to CoV-2-SARS by consecutive
screening in routine care of out and inpatients with chronic inflammatory rheumatism (i.e.
rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis) by serological testing
and to compare prevalence according to type of chronic inflammatory rheumatism, DMARD class
and symptomatic treatment (corticosteroid therapy, NSAIDs).
Inclusion criteria:
- Patient with chronic inflammatory rheumatic disease (i.e. rheumatoid arthritis, psoriatic
rheumatism, axial spondyloarthritis), Coming for consultation or hospitalization as part of
the usual follow-up of his condition
Exclusion criteria:
- Adult patient under legal protection (guardianship, curatorship)
Centre hopsitalier universitaire de Montpellier
Montpellier, Occitanie, France